Literature DB >> 9112235

Autoantibodies recognizing proteins copurified with PCNA in patients with connective tissue diseases.

K Takeuchi1, K Kaneda, I Kawakami, Y Takasaki.   

Abstract

OBJECTIVE: Proliferating cell nuclear antigen (PCNA), one of the target antigen recognized by lupus sera, has been reported to be present as a subnuclear multi-peptide complex. But autoantibodies reacting with components of PCNA complex are poorly understood. To study the specificity of those autoantibodies, immunoreactivities of autoimmune sera against purified PCNA antigen were studied.
METHODS: PCNA antigens were purified from rabbit thymus extract by affinity column using murine monoclonal antibodies (mAbs) to PCNA, TOB7, TO17 and TO30. Immunoreactivities of autoimmune sera against purified PCNA were analyzed by WB.
RESULTS: PCNA antigen purified by serum AK predominantly showed a 34 kD band specific for PCNA in SDS-PAGE. When antigens were purified by anti-PCNA mAb TOB7 and TO30 which are known to be targeting different epitopes on PCNA antigen, SDS-PAGE analysis showed various mol. wt of proteins in addition to the 34 kD PCNA while both AK and mAbs reacted only with 34 kD PCNA in WB. In WB using PCNA purified by TOB7, various immunoreactivities were observed at 150, 66, 58, 48, 45, 37, 32 and 16 kDa in sera from patients with connective tissue diseases.
CONCLUSIONS: These results suggested that many of the proteins copurified with PCNA were also targets of autoimmune responses and these autoantibody expression may be induced through antigen-driven mechanisms.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9112235     DOI: 10.1007/bf00351175

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  14 in total

1.  Autoantibody to a nuclear antigen in proliferating cells.

Authors:  K Miyachi; M J Fritzler; E M Tan
Journal:  J Immunol       Date:  1978-12       Impact factor: 5.422

2.  A sandwich type enzyme-linked immunosorbent assay for proliferating cell nuclear antigen (PCNA)/cyclin using monoclonal antibodies.

Authors:  Y Takasaki; M Ohgaki; A Kodama; K Ogata; H Hashimoto; T Shirai; S Hirose
Journal:  J Immunol Methods       Date:  1990-09-14       Impact factor: 2.303

3.  Analysis of the epitopes of proliferating cell nuclear antigen recognized by monoclonal antibodies.

Authors:  G Roos; G Landberg; J P Huff; R Houghten; Y Takasaki; E M Tan
Journal:  Lab Invest       Date:  1993-02       Impact factor: 5.662

4.  Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen.

Authors:  M L Smith; I T Chen; Q Zhan; I Bae; C Y Chen; T M Gilmer; M B Kastan; P M O'Connor; A J Fornace
Journal:  Science       Date:  1994-11-25       Impact factor: 47.728

5.  Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta.

Authors:  R Bravo; R Frank; P A Blundell; H Macdonald-Bravo
Journal:  Nature       Date:  1987 Apr 2-8       Impact factor: 49.962

6.  Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair.

Authors:  R Li; S Waga; G J Hannon; D Beach; B Stillman
Journal:  Nature       Date:  1994-10-06       Impact factor: 49.962

7.  Clinical features of patients with antibodies directed against proliferating cell nuclear antigen.

Authors:  M J Fritzler; G A McCarty; J P Ryan; T D Kinsella
Journal:  Arthritis Rheum       Date:  1983-02

Review 8.  Antinuclear antibodies (ANAs): diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity.

Authors:  E M Tan; E K Chan; K F Sullivan; R L Rubin
Journal:  Clin Immunol Immunopathol       Date:  1988-05

9.  A human autoimmune protein associated with U1 RNA contains a region of homology that is cross-reactive with retroviral p30gag antigen.

Authors:  C C Query; J D Keene
Journal:  Cell       Date:  1987-10-23       Impact factor: 41.582

10.  Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21.

Authors:  Y Li; C W Jenkins; M A Nichols; Y Xiong
Journal:  Oncogene       Date:  1994-08       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.